Table 4 Risk ratio of specific adverse events after the combination of lenvatinib and pembrolizumab
ADE | AGI and ICI | AGI, no ICI | no AGI, ICI | no AGI, no ICI |
|---|---|---|---|---|
All haemorrhage ADE | 420/19,865 | 1188/43,623 | 952/129,702 | 383,045/38,222,865 |
Tumour haemorrhage | 31/19,865 | 116/43,623 | 66/129,702 | 1740/38,222,865 |
Small intestinal haemorrhage | 5/19,865 | 5/43,623 | 18/129,702 | 1207/38,222,865 |
Tracheal haemorrhage | 3/19,865 | 20/43,623 | 3/129,702 | 190/38,222,865 |